2024-11-13 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**1. Performance Overview**

**Company Overview:** Intuitive Surgical Inc. is a leading provider of robotic-assisted surgical systems and instruments for minimally invasive surgery.

**Performance Comparison:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) | Cumulative Return (ISRG) | Cumulative Return (VOO) |  Difference  | Relative IGD |
|------------|------|-------|------|-------|---------|--------------------------|--------------------------|--------------|---------------|
| 2015-2017  | 108.3% | 16.7% | 69.9% | 0.8 | 43.3 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2016-2018  | 162.5% | 23.9% | 130.2% | 1.2 | 56.9 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2017-2019  | 176.3% | 23.9% | 124.6% | 1.4 | 70.2 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2018-2020  | 118.0% | 40.4% | 70.7% | 1.2 | 97.1 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2019-2021  | 131.3% | 40.4% | 31.3% | 1.2 | 128.0 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2020-2022  | 33.3% | 45.8% | 9.7% | 1.2 | 94.5 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2021-2023  | 26.5% | 45.8% | -8.4% | 1.4 | 120.2 |  N/A                    |  N/A                    |  N/A          |  N/A           |
| 2022-2024  | 49.2% | 45.1% | 18.7% | 1.3 | 190.8 | 388.29                  | 179.55                  | 208.74       | 78.07          |

**Analysis:**  ISRG has significantly outperformed the S&P 500 (VOO) over the recent period, with a cumulative return of 388.29% compared to 179.55% for the S&P 500. This translates to a difference of 208.74%, indicating a strong outperformance, particularly in the last year. The relative IGD score of 78.07 suggests that ISRG's current performance is in the upper 78th percentile of its historical performance range, indicating a high relative strength compared to its own past performance. 

**2. Recent Price Movement**

| Metric             | Value |
|--------------------|-------|
| Closing Price     | 537.04|
| 5-Day Moving Avg | 529.81|
| 20-Day Moving Avg | 513.31|
| 60-Day Moving Avg | 494.12|

**Analysis:** ISRG's recent price movement suggests a bullish trend. The stock is currently trading above all three moving averages, with the closing price at 537.04 significantly higher than the 60-day moving average of 494.12. 

**3. Technical Indicators**

| Indicator | Value | Analysis |
|---|---|---|
| RSI | 72.56 |  The RSI value of 72.56 indicates the stock is in overbought territory, suggesting a potential short-term correction might be on the horizon. However, given the strong upward trend and continued outperformance, a correction might not necessarily signal a bearish trend.  |
| PPO | 0.42 | A positive PPO value of 0.42 suggests bullish momentum, confirming the upward trend indicated by the moving averages and price action. |
| Delta_Previous_Relative_Divergence | 13.01 (+) |  A positive delta of 13.01 suggests a short-term upward trend in relative strength, indicating that ISRG is continuing to outperform its historical average. |
| Expected Return | 10.41% |  A 10.41% expected return suggests that, based on historical data and current trends, ISRG is anticipated to outperform the S&P 500 by a significant margin over the long term (2 years or more). |

**4. Recent Earnings and Outlook**

| Date        | EPS     | Revenue        |
|-------------|---------|-----------------|
| 2024-10-18 | 1.59    | $2.04 B$       |
| 2024-07-19 | 1.48    | $2.01 B$       |
| 2024-04-19 | 1.54    | $1.89 B$       |
| 2023-10-20 | 1.18    | $1.74 B$       |

**Analysis:** ISRG has consistently delivered strong earnings results with revenue exceeding $2 billion in the past three quarters.  The latest earnings release for the quarter ending on October 18, 2024, showed an EPS of 1.59, exceeding analyst estimates. 

**5. Financial Information**

**Revenue and Profitability:**

| Quarter     | Revenue | Profit Margin |
|-------------|---------|---------------|
| 2024-09-30 | $2.04B  | 67.41%       |
| 2024-06-30 | $2.01B  | 68.30%       |
| 2024-03-31 | $1.89B  | 65.87%       |
| 2023-12-31 | $1.93B  | 66.24%       |
| 2023-09-30 | $1.74B  | 66.94%       |

**Capital and Profitability:**

| Quarter     | Equity | ROE   |
|-------------|--------|-------|
| 2024-09-30 | $15.58B| 3.63% |
| 2024-06-30 | $14.71B| 3.58% |
| 2024-03-31 | $13.96B| 3.90% |
| 2023-12-31 | $13.31B| 4.56% |
| 2023-09-30 | $12.54B| 3.32% |

**Analysis:** ISRG demonstrates strong profitability with consistent high profit margins and a robust financial position. The company continues to increase its revenue and maintains a healthy equity level, further solidifying its financial stability.

**6. News and Recent Issues**

**Latest Earnings News:**

* ISRG reported strong Q3 2024 earnings on October 18th, exceeding analyst expectations on both EPS and revenue. The company highlighted a growing installed base of da Vinci surgical systems and increasing procedure volume. [Source: Shacknews]

**Recent Market Outlook:**

* Finbold reported that analysts remain bullish on ISRG's long-term prospects, citing its dominance in the robotic surgery market and expanding global reach. [Source: Finbold]

**Analyst Opinions and Performance Highlights:**

*  Analysts have a consensus Strong Buy rating on ISRG. [Source: TipRanks]
*  Several analysts recently raised their price targets for ISRG, reflecting confidence in the company's growth trajectory. [Source: Yahoo Finance]

**7. Overall Analysis**

ISRG is a strong performer with a robust financial position and consistent earnings growth. Its dominance in the robotic surgery market, coupled with a growing installed base and increasing procedure volume, suggests continued strong performance. While technical indicators suggest potential short-term volatility, the company's long-term prospects remain bright, supported by the continued adoption of minimally invasive surgical techniques.  Overall, ISRG presents a compelling investment opportunity for investors seeking exposure to the healthcare sector and with a long-term investment horizon.

**8. Recommendations**

Based on the current data, ISRG appears to be a strong buy for long-term investors seeking growth potential within the healthcare sector. While the company's valuation is slightly higher than its peers, its strong performance and market position justify the premium. However, investors should remain aware of potential short-term volatility due to the stock's recent strong performance and overbought technical indicators. 
